Carcinogenicity study of auranofin, an orally administered gold compound, in mice.
Auranofin, a gold-containing compound, was administered to Charles River CD-1 mice for 18 months to assess its possible carcinogenicity. The mice were dosed orally with 1.0, 3.0, or 6.0 (increased to 9.0 on Day 294) mg/kg/day. Each dose group and each of two control groups contained 110 males and 110 females. Survival was greater than 70% at the end of the study. No effect of the treatment on neoplastic or nonneoplastic lesions was found. This is in contrast to the results reported in rats. Auranofin in rats produced a heavy metal nephropathy characterized by acute coagulative necrosis, subacute renal cortical fibrosis, chronic cytomegaly and karyomegaly, and finally renal cortical neoplasia (adenomas and adenocarcinomas). The lack of effect of auranofin on tumor incidence in mice suggests the findings in rats may be species specific.
Markiewicz
V R
VR
Hazleton Laboratories America, Inc., Vienna, Virginia 22180.
Saunders
L Z
LZ
Geus
R J
RJ
Payne
B J
BJ
Hook
J B
JB
D000284:Administration, Oral; D000818:Animals; D001310:Auranofin / Q000008:administration & dosage / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests; D002273:Carcinogens; D004435:Eating / Q000187:drug effects; D005260:Female; D007672:Kidney Cortex / Q000033:anatomy & histology / Q000187:drug effects; D008297:Male; D051379:Mice; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology; D012737:Sex Factors; D013997:Time Factors
D002273:Carcinogens; D001310:Auranofin